Biology validated.
Metabolic surgery established the intestine as a powerful regulator of whole-body metabolism.

Market validated.
GLP-1/GIP therapies demonstrated enormous demand for effective obesity pharmacotherapy.

Unmet need remains.
Persistence, tolerability, lean-mass preservation, chronic systemic exposure and heterogeneous response leave room for complementary approaches.

Technology ready.
Elaphron’s prior GI drug-development experience and locally acting platform create an opportunity to translate this biology pharmacologically.

Next step.

Following FDA interaction, Elaphron is advancing the IND-enabling studies requested to support EL-924 clinical development, with the objective of moving into prospective human testing.

Near-term clinical objective: determine whether the rapid improvement in insulin resistance observed in early uncontrolled human experience can be reproduced in a controlled clinical study—before substantial weight loss.

FDA Feedback → IND-Enabling Studies → IND → Controlled Human Validation